Oncotalks hematology videos and news

SABC

Interviews recorded at the San Antonio Breast Cancer Symposium

SABCS 2019 Francois Duhoux; A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC)

SABCS 2019 Francois Duhoux; A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC)

Francois Duhoux is commenting on the abstract: PD7-09 A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)
SABC , Kisqali Channel , Lithuania , Albania
00:04:53
SABCS 2019 - JoaquiÌn Gavilá (EN); GS2-05 Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study

SABCS 2019 - JoaquiÌn Gavilá (EN); GS2-05 Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study

JoaquiÌn Gavilá is commenting on the abstract: GS2-05 Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study
SABC , Kisqali Channel , Lithuania , Albania
00:03:35
SABCS 2019 - JoaquiÌn Gavilá (ES); Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study

SABCS 2019 - JoaquiÌn Gavilá (ES); Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study

JoaquiÌn Gavilá is commenting on the abstract: GS2-05 Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study
SABC , Lithuania , Albania
00:04:12
  • 1
  • 2
  • »

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies . If you require further information and/or do not wish to have cookies placed when using the site, visit Privacy Notice.

On acceptance: use all cookie settings
On denial: use only necessary cookies